Radiation via Monoclonal Antibodies: Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 November 2024

29 March 2024

  • curprev 23:2923:29, 29 March 2024‎ Lazy talk contribs‎ 2,149 bytes −64‎ No edit summary
  • curprev 21:3721:37, 29 March 2024‎ Lazy talk contribs‎ 2,213 bytes −464‎ No edit summary
  • curprev 21:3521:35, 29 March 2024‎ Lazy talk contribs‎ 2,677 bytes +2,677‎ Created page with "<includeonly> {| class="wikitable" |- ! Property !! Information |- | Drug Name || Radiation via Monoclonal Antibodies |- | FDA Approval || Under research, not yet FDA-approved for general use |- | Used for || Glioblastoma (GBM) and potentially other high-grade glioma tumors |- | Clinical Trial Phase || Various phases, with some treatments in early clinical trials |- | Common Side Effects || Side effects vary depending on the specific monoclonal antibody and radioactive c..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Radiation_via_Monoclonal_Antibodies"